NCT00627458View on ClinicalTrials.gov

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

403

Participants

Timeline

Start Date

February 1, 2008

Primary Completion Date

August 18, 2008

Study Completion Date

August 18, 2008

Conditions
Acellular PertussisDiphtheriaPoliomyelitisHaemophilus Influenzae Type bTetanusHepatitis B
Interventions
BIOLOGICAL

Infanrix Hexa

Vaccine administered as a booster dose at 16-20 months of age

Trial Locations (6)

20520

GSK Investigational Site, Turku

28100

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

90220

GSK Investigational Site, Oulu

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY